Latvian Institute of Organic Synthesis, Laboratory of Pharmaceutical Pharmacology, Riga, Latvia.
J Diabetes Complications. 2013 May-Jun;27(3):262-7. doi: 10.1016/j.jdiacomp.2012.12.002. Epub 2013 Jan 23.
The present study was undertaken to investigate the relationship between glyoxalase 1 (Glo1) enzyme activity and painful diabetic neuropathy (DN) in patients with diabetes mellitus.
Glo1 activity and biochemical markers were determined in blood samples from 108 patients with type 1 diabetes, 109 patients with type 2 diabetes, and 132 individuals without diabetes as a control. Painful and painless peripheral DN was assessed and multivariate regression analysis was used to determine independent association of Glo1 activity with occurrence of painful DN.
In patients with type 1 and type 2 diabetes mellitus and painful DN compared to patients with painless DN, Glo1 activity was significantly reduced by 12 and 14%, respectively. The increase in Glo1 activity was significantly associated with reduced occurrence of painful DN after adjusting for confounders by multivariate analysis.
Our results demonstrate for the first time that Glo1 activity is lower in patients with both types of diabetes mellitus who were diagnosed with painful DN. These data support the hypothesis that Glo1 activity modulates the phenotype of DN and warrant further investigation into the role of Glo1 in DN.
本研究旨在探讨糖氧还蛋白 1（Glo1）酶活性与糖尿病患者伴发痛性糖尿病周围神经病变（DN）之间的关系。
测定了 108 例 1 型糖尿病患者、109 例 2 型糖尿病患者和 132 名无糖尿病对照者的血液样本中的 Glo1 活性和生化标志物。评估了痛性和无痛性周围 DN，并采用多元回归分析确定 Glo1 活性与痛性 DN 发生的独立相关性。
与无痛性 DN 患者相比，1 型和 2 型糖尿病伴痛性 DN 患者的 Glo1 活性分别显著降低了 12%和 14%。通过多元分析调整混杂因素后，Glo1 活性的增加与痛性 DN 发生的减少显著相关。
我们的研究结果首次表明，患有痛性 DN 的 1 型和 2 型糖尿病患者的 Glo1 活性降低。这些数据支持 Glo1 活性调节 DN 表型的假说，并需要进一步研究 Glo1 在 DN 中的作用。
